Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pirfenidone
Drug: Nintedanib
Drug: GLPG4716

First Posted Date: 2021-07-21

Last Posted Date: 2022-06-02

Lead Sponsor: Galapagos NV

Target Recruit Count: 58

Registration Number: NCT04971746

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14]GLPG3970 oral solution
Drug: GLPG3970 film-coated tablet
Drug: [14C]GLPG3970 solution for infusion

First Posted Date: 2021-05-28

Last Posted Date: 2021-07-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 6

Registration Number: NCT04907149

Locations: 🇬🇧
Quotient Sciences Ltd, Nottingham, United Kingdom

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3121
Drug: Placebo

First Posted Date: 2021-04-23

Last Posted Date: 2021-12-03

Lead Sponsor: Galapagos NV

Target Recruit Count: 50

Registration Number: NCT04856358

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667
Drug: Midazolam

First Posted Date: 2021-02-03

Last Posted Date: 2021-03-03

Lead Sponsor: Galapagos NV

Target Recruit Count: 14

Registration Number: NCT04736927

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Sulfasalazine
Drug: GLPG3970

First Posted Date: 2021-01-22

Last Posted Date: 2021-07-14

Lead Sponsor: Galapagos NV

Target Recruit Count: 8

Registration Number: NCT04720183

Locations: 🇺🇸
Biotral Inc, Newark, New Jersey, United States

A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3970 oral solution
Drug: GLPG3970 tablet

First Posted Date: 2021-01-13

Last Posted Date: 2021-03-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT04708184

Locations: 🇫🇷
Biotral Rennes, Rennes, France

Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1205 film-coated tablets
Drug: GLPG1205 capsules
Drug: [14C]-GLPG1205 solution for infusion

First Posted Date: 2021-01-12

Last Posted Date: 2021-03-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT04704739

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus

Phase 1

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: GLPG3970 film-coated tablet
Drug: Placebo film-coated tablet

First Posted Date: 2021-01-07

Last Posted Date: 2021-10-21

Lead Sponsor: Galapagos NV

Target Recruit Count: 11

Registration Number: NCT04700267

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇵🇱
Medycyna Kliniczna, Warszawa, Poland
🇺🇦
Medical Centre of Ltd Liability Comp, Kyiv, Ukraine

and more 11 locations

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

Phase 2

Terminated

Conditions: Primary Sjögren Syndrome

Interventions: Drug: Placebo
Drug: GLPG3970

First Posted Date: 2021-01-07

Last Posted Date: 2023-09-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 31

Registration Number: NCT04700280

Locations: 🇭🇺
Debreceni Egyetem, Debrecen, Hungary
🇵🇱
Szpital Uniwersytecki nr 2 im.dr J. Biziela, Bydgoszcz, Poland
🇵🇱
NZOZ Centrum Medyczne Reuma Park, Warsaw, Poland

and more 7 locations

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: GLPG4399 oral suspension
Drug: GLPG4399 capsules

First Posted Date: 2020-12-04

Last Posted Date: 2022-02-01

Lead Sponsor: Galapagos NV

Target Recruit Count: 88

Registration Number: NCT04653467

Locations: 🇨🇦
Altasciences Montreal, Mont-Royal, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy